An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects. Researchers from The University of Texas MD Anderson Cancer Center presented interim findings of the multi-center Phase 2 study at the 54th American Society of Hematology Annual Meeting and Exposition. "I believe we are witnessing a breakthrough in mantle cell lymphoma. This is great news for patients," said Michael Wang, M.D...
More...
More...